Other

Cerenis Therapeutics Holding S.a.

Esperion Therapeutics, Inc.

Abionyx Pharma Sa

Pfizer Corporation

Jean-louis Dasseux

Abionyx Pahrma Sa

Jean-Louis Henri Dasseux

Renate Sekul

Isabelle Cornut

Jean Dufourcq

Carmen Daniela Oniciu

G&uuml;nther Metz

Klaus B&uuml;ttner

Klaus Büttner

Daniela Carmen Oniciu

Günther Metz

Ronald Barbaras

Rose Ackermann

Lingyu Zhu

Anna Shenderova Schwendeman

Otto Joseph Geoffroy

Anna Rzepiela

Oleg Gennadievich Rodin

Laura Calabresi

Cyrille Tupin

Constance Peyrottes

Valery Kochubey

Dmitry Kovalsky

Otto Geoffroy

Disclosed herein is the use of CER-001, a negatively charged lipoprotein complex which comprises recombinant human apolipoprotein A-I (ApoA-I), sphingomyelin (SM), and 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DPPG) for treating kidney diseases, and methods for treating a subject having kidney diseases with CER-001. For example, the kidney disease can be associated with a lecithin cholesterol acyl transferase (LCAT) deficiency.

CER-001 therapy for treating kidney disease

The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.

Lipoprotein complexes and manufacturing and uses thereof

This invention provides compounds, for example, of Formulae (A)-(H) and (J)-(AA) and pharmaceutically acceptable salts, solvates, esters, amides, and prodrugs thereof. The invention further provides pharmaceutical compositions comprising a compound of the invention, and a pharmaceutically acceptable carrier or vehicle. The compounds and compositions disclosed herein are useful for treating or preventing various diseases and conditions, for example liver disease such as liver fibrosis, fatty liver disease, non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), and kidney diseases such as acute kidney injury (AKI).

Compounds useful for treating liver diseases

Lipid binding protein based complexes for carrying cyclic dinucleotides (CDNs) and uses thereof, pharmaceutical compositions comprising the complexes, and methods of making the complexes.

Complexes for delivery of cyclic dinucleotides

The present disclosure provides charged lipoprotein complexes that include as one component a negatively charged phospholipid that is expected to impart the complexes with improved therapeutic properties.

Charged lipoprotein complexes and their uses

Disclosed herein is the use of CER-001, a negatively charged lipoprotein complex which comprises recombinant human apolipoprotein A-I (ApoA-I), sphingomyelin (SM), and 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (Dipalmitoylphosphatidyl-glycerol; DPPG) for treating kidney diseases, and methods for treating a subject having kidney diseases with CER-001. For example, the kidney disease can be associated with a lecithin cholesterol acyl transferase (LCAT) deficiency.

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Hydroxyl compounds and compositions for cholesterol management and related uses

The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or preventing a disease or disorder, which comprises administering a therapeutically or prophylactically effective amount a compound described herein.

Compounds, compositions and methods useful for cholesterol mobilization

Growing community of inventors

Toulous, France

Jean-Louis Henri Dasseux